LeserbriefKommentar
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer—Reply
JAMA · 2024
DOI: 10.1001/jama.2024.15500 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2024. Verfasst von Wendy Y Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, Massachusetts. Hauptthemen laut MEDLINE: Breast Neoplasms, Aspirin. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Breast NeoplasmsAspirinHumansFemaleChemotherapy, AdjuvantAnti-Inflammatory Agents, Non-Steroidal
Substanzen
AspirinAnti-Inflammatory Agents, Non-Steroidal
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, Massachusetts.
- Mayo Clinic, Rochester, Minnesota.
- Brigham and Women's Hospital, Boston, Massachusetts.
Zitieren
APA
Chen, W. Y., Ballman, K. V., & Holmes, M. D. (2024). Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer—Reply. JAMA. https://doi.org/10.1001/jama.2024.15500
Vancouver
Chen WY, Ballman KV, Holmes MD. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer—Reply. JAMA. 2024. doi:10.1001/jama.2024.15500
BibTeX
@article{Chen2024,
author = {Chen, Wendy Y and Ballman, Karla V and Holmes, Michelle D},
title = {Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer—Reply},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.15500}
}
EUVIMED